156154-10-8

Usage

Chemical origin

Derived from piperazine, a heterocyclic amine.

Core structure

Consists of a 1,4-benzodioxin core, which is a six-membered ring fused to a five-membered ring containing two oxygen atoms.

Molecular composition

A piperazine derivative with the benzodioxin core.

Pharmaceutical applications

Has potential pharmaceutical applications due to its pharmacological properties.

Serotonin receptor agonist

Studied for its potential as a serotonin receptor agonist, which may have implications for the treatment of various conditions.

Treatment of disorders

Investigated for its potential use in the treatment of neurological and psychiatric disorders.

Research interest

The chemical structure and properties of 1,4-Benzodioxin, piperazine deriv. make it a subject of interest for researchers and pharmaceutical companies.

Drug development

Its unique structure and properties are being explored for the development of new drugs targeting specific receptors and conditions.

Upstream product

• 75-75-2 methanesulfonic acid 
• 74191-85-8 doxazosin 
• 105314-71-4 (+)-Doxazosin hydrochloride 
• 4739-94-0 ethyl 2,3-dihydro-1,4-benzodioxin-2-carboxylate 
• 120-80-9 benzene-1,2-diol 
• 70918-54-6 (S)‐1,4‐benzodioxane‐2‐carboxylic acid 
• 401947-96-4 (S)-2,3-dihydrobenzo[1,4]dioxine-2-carbonyl chloride 
• 3663-80-7 1,4-benzodioxane-2-carboxylic acid 
• 1246188-97-5 (2,3-dihydrobenzo[b][1,4]dioxin-2-yl)(1H-imidazol-1-yl)methanone 
• 401941-54-6 (S)-N-(1,4-benzodioxan-2-carbonyl)piperazine 

Relevant academic research and scientific papers

Process for the Preparation of Doxazosin and Salts Thereof

The present invention relates to a process for the preparation of doxazosin or salts thereof.

CRYSTALLINE POLYMORPH OF DOXAZOSIN MESYLATE (FORM IV) AND PROCESS FOR PREPARATION THEREOF

Crystalline Form (IV) of doxazosin mesylate, a process for its preparation and uses thereof.

Conversion of modification D to modification A of doxazosin mesylate

A process for preparing doxazosin mesylate in modification A which comprises dissolving doxazosin with methanesulfonic acid in methanol or a mixture of an aprotic, polar organic solvent and methanol, removing any turbidity from the resulting solution, and

Medicaments containing doxazosin mesylate of crystalline modification D

Drugs comprising modification D of doxazosin mesylate are described. They are suitable for treating high blood pressure.

Practical chemical and enzymatic technologies for (S)-1,4-benzodioxan-2-carboxypiperizine intermediate in the synthesis of (S)-doxazosin mesylate

(S)-1,4-Benzodioxan-2-carboxypiperazine (S)-2, the key chiral intermediate for the synthesis of (S)-doxazosin, was prepared utilizing two approaches: (i) enzymatic resolution of ethyl 1,4-benzodioxan-2-carboxylate with an esterase (Serratia) followed by amide formation; (ii) direct resolution of 1,4-benzodioxan-2-carboxypiperazine 2 with D-tartaric acid. An efficient process for the conversion of (S)-2 to (S)-doxazosin mesylate was developed (80% yield, 99.9% e.e.).

Polymorphic form of doxazosin mesylate (form III)

A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 8.49 DEG , 11.72 DEG , 16.03 DEG

Crystalline form of the doxazosin mesylate and process for its production

The invention refers to a crystalline form of the doxazosin mesylate and to a process for its production by hot treating with methanesulfonic acid doxazosin suspended in a solvent selected from the alcohols, straight or branched, from C1to Csu